0001209191-20-036981.txt : 20200616 0001209191-20-036981.hdr.sgml : 20200616 20200616162947 ACCESSION NUMBER: 0001209191-20-036981 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200616 FILED AS OF DATE: 20200616 DATE AS OF CHANGE: 20200616 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WILSON TROY EDWARD CENTRAL INDEX KEY: 0001589597 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39321 FILM NUMBER: 20966792 MAIL ADDRESS: STREET 1: C/O KURA ONCOLOGY, INC. STREET 2: 3033 SCIENCE PARK RD, SUITE 220 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Avidity Biosciences, Inc. CENTRAL INDEX KEY: 0001599901 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461336960 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10975 N. TORREY PINES RD., STREET 2: #150 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-401-7900 MAIL ADDRESS: STREET 1: 10975 N. TORREY PINES RD., STREET 2: #150 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: Avidity Biosciences LLC DATE OF NAME CHANGE: 20161227 FORMER COMPANY: FORMER CONFORMED NAME: Avidity NanoMedicines LLC DATE OF NAME CHANGE: 20140211 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-16 0 0001599901 Avidity Biosciences, Inc. RNA 0001589597 WILSON TROY EDWARD C/O AVIDITY BIOSCIENCES, INC. 10975 N. TORREY PINES RD., SUITE 150 LA JOLLA CA 92037 1 0 0 0 Common Stock 2020-06-16 4 C 0 189042 A 805301 I By family trust Common Stock 189618 D Common Stock 35553 I By trust FBO Child 1 Common Stock 35553 I By trust FBO Child 2 Common Stock 11851 I By trust FBO Child 3 Common Stock 11851 I By trust FBO Child 4 Series A Preferred Stock 2020-06-16 4 C 0 254907 D Common Stock 120837 0 I By family trust Series B Preferred Stock 2020-06-16 4 C 0 35374 D Common Stock 16769 0 I By family trust Series C Preferred Stock 2020-06-16 4 C 0 108504 D Common Stock 51436 0 I By family trust The shares of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. Includes 59,256 shares subject to repurchase by the Issuer, which shares will vest in 15 equal monthly installments beginning on June 29, 2020. /s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact 2020-06-16